ADC Therapeutics (ADCT) Short term Debt (2020 - 2026)

ADC Therapeutics (ADCT) posted Short term Debt of $4.6 million for Q1 2026, up 54.5% sequentially from $3.0 million in Q4 2025.

ADC Therapeutics (ADCT) Short term Debt (2020 - 2026) Analysis & Trends

ADC Therapeutics has reported Short term Debt for 6 years, with the latest figure at $4.6 million in Q1 2026.

Quarterly Short term Debt changed N/A year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (changed N/A YoY) and the FY2025 annual result came in at $3.0 million, changed N/A from the prior year.
Short term Debt rose to $4.6 million in Q1 2026 per ADCT's latest filing, from $3.0 million in the prior quarter.
Over five years, Short term Debt peaked at $14.3 million in Q3 2023 and troughed at $3.0 million in Q4 2025.
A 4-year average of $9.7 million and a median of $12.5 million in 2022 frame the typical range for Short term Debt.
The sharpest annual moves came in 2022 and 2023: Short term Debt advanced 6.14% in 2022, then surged 111.47% in 2023.
Over 4 years, Short term Debt stood at $12.5 million in 2022, then climbed by 14.87% to $14.3 million in 2023, then slumped by 79.06% to $3.0 million in 2025, then surged by 54.5% to $4.6 million in 2026.
According to Business Quant data, Short term Debt over the past three periods registered $4.6 million, $3.0 million, and $14.3 million for Q1 2026, Q4 2025, and Q3 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.40 Bn	131.55 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.53 Bn	78.54 Bn	3.93 Bn
3	Argenx Se	65.20 Bn	60.02 Bn	1.37 Bn
4	Moderna	60.40 Bn	55.26 Bn	52.00 Mn
5	BeOne Medicines	42.17 Bn	37.07 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.36 Bn	28.05 Bn	992.69 Mn
7	BioNTech SE	28.74 Bn	10.34 Bn	668.28 Mn
8	Insmed	27.45 Bn	26.29 Bn	358.27 Mn
9	Royalty Pharma	27.17 Bn	26.33 Bn	-
10	ADC Therapeutics	153.25 Mn	-65.86 Mn	17.14 Mn

Download Data